Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: BRTX is a clinical-stage biotechnology company developing cell and tissue-based therapeutic products, primarily using adult stem cells. Its core programs include the Disc/Spine Program (lead candidate BRTX-100 for chronic lower back pain) and the ThermoStem Program (pre-clinical treatment for metabolic disorders like obesity and type 2 diabetes). The company also operates a commercial biocosmeceuticals business.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenues | $359,700 | $401,000 |
| Net Loss | $(14,241,975) | $(8,979,381) |
| Operating Expenses | $15,982,988 | $11,928,122 |
| Research & Development | $10,094,671 | $6,706,913 |
| Cash & Cash Equivalents (Dec 31, 2025) | $1,511,188 | $547,890 |
| Working Capital (Deficit) | $(586,029) | $7,395,815 |
| Accumulated Deficit | $(169,920,690) | $(155,678,715) |
Note: The filing text does not provide a specific "profit margin" as the company is pre-profit. Gross profit for 2025 was $335,856.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss widened by approximately $5.26 million (58% increase) to $14.24 million, driven primarily by higher R&D and G&A expenses.
- R&D Expense Surge: R&D expenses increased by $3.39 million (51%) to $10.09 million, largely due to increased recruitment and costs for the Phase 2 clinical trial of BRTX-100.
- Revenue Decline: Total revenue decreased by $41,300 (10%) to $359,700, primarily due to a decrease in royalty revenue from disc procedures.
- Liquidity Shift: The company moved from a positive working capital position of $7.4 million in 2024 to a deficit of $0.6 million in 2025. This was caused by a significant drawdown in marketable securities (from $10.18M to $1.44M) to fund operations.
- Non-Cash Gains: The company recognized a $1.12 million gain on the change in fair value of warrant liabilities in 2025, compared to $97,188 in 2024. The 2024 period included a one-time $1.71 million gain on the exchange of warrants, which did not recur in 2025.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Phase 2 Trial Completion: Enrollment of 99 patients in the Phase 2 clinical trial for BRTX-100 was completed in February 2026.
- Regulatory Pathway: Following a Type B meeting with the FDA in December 2025, the company initiated Phase 3 enabling activities with a goal to submit a Phase 3 IND during 2026.
- Capital Needs: Management states current funds are insufficient to complete development efforts for the next 12 months. Significant additional financing is required to fund Phase 3 trials and operations.
Risks and Contingencies
- Going Concern: The independent auditor has issued an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern within 12 months of the filing date due to recurring losses and working capital deficits.
- Nasdaq Delisting Risk: On March 26, 2026, the company received notice from Nasdaq of non-compliance with the minimum bid price requirement ($1.00/share). The company has a 180-day grace period to regain compliance or face delisting.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting, including lack of adherence to formal policies and ineffective controls over journal entries and reconciliations.
Unusual Items
- Subsequent Financing: In February 2026, the company completed a public offering raising approximately $5.0 million in gross proceeds. This occurred after the balance sheet date.
- Stock Repurchase Program: Authorized in June 2025 to repurchase up to $2 million of stock; no shares had been repurchased as of the filing date.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $5.0 million raised in February 2026 to fund the Phase 3 IND submission and ongoing operations given the "substantial doubt" going concern warning.
- Nasdaq Compliance: Monitor the company's ability to regain compliance with the $1.00 minimum bid price requirement by September 22, 2026, to avoid delisting.
- Clinical Data: Review the full data readout from the completed Phase 2 trial (99 patients) to assess the probability of FDA approval and the feasibility of the Phase 3 plan.
- Internal Controls: Assess the progress of remediation efforts regarding the material weaknesses in financial reporting controls.
- Dilution: Evaluate the impact of the February 2026 offering (12.5M shares + warrants) and existing warrant liabilities on shareholder dilution.